MiniMed Group, Inc.

MiniMed Group reported fiscal year 2026 revenue of $3.1 billion, an increase from $2.7 billion in fiscal year 2025. However, the company's net loss widened to $317 million in FY2026 from $198 million in FY2025, and Adjusted EBITDA decreased to $202 million. The company continues to expand its diabetes management solutions, launching new CGM sensors and insulin pumps, and advancing its next-generation dosing algorithms, while also highlighting significant market growth potential.

MiniMed Group expanded its Board of Directors from nine to eleven members and appointed David Endicott and Linnea Burman as new directors, effective June 29, 2026. Endicott, CEO of Alcon, will serve as a Class I director, while Burman, Senior VP at Medtronic, will be a Class II director. The company also announced its 2026 Annual Meeting of Stockholders will be held virtually on October 9, 2026, with a record date of August 11, 2026, and deadlines for stockholder proposals and nominations in July 2026.

MiniMed Group, Inc. reported strong financial results for its fourth quarter and full fiscal year 2026, with Q4 net sales reaching $837 million, a 15.6% increase as reported and 8.7% organic year-over-year. The company achieved record annual net sales of $3.102 billion, growing 14.2% as reported and 8.0% organic. Key highlights include global launches of MiniMed Flex™, Instinct, and MiniMed Go™ Smart MDI, along with an extended partnership with Abbott. For fiscal year 2027, MiniMed expects approximately 10% organic revenue growth and an adjusted EBITDA margin of 16%.

MiniMed Group, Inc. announced that Brett Wall will resign from its Board of Directors, effective July 3, 2026, due to his departure from Medtronic plc. Concurrently, Scott Cundy was appointed to the Board, effective July 3, 2026, to fill the vacancy. Mr. Cundy, who is Senior Vice President and Chief Quality, Development, and Innovation Officer at Medtronic, will serve as a Class II director and join the Nominating and Corporate Governance Committee.

MiniMed Group, Inc. announced Health Canada has licensed new software for its MiniMed™ 780G system, significantly advancing diabetes care in Canada. The updated system now offers greater flexibility, combining Meal Detection™ and SmartGuard™ with Guardian™ 4 and Simplera Sync™ sensors. It is also compatible with Fiasp® and indicated for adults 18 years and older with Type 2 diabetes, expanding its market.

Medtronic plc, the parent company of MiniMed Group, Inc., disclosed that an unauthorized third party accessed data in some of its IT systems. Medtronic promptly contained the incident and engaged cybersecurity experts, reporting no impact on products, patient safety, or operations, and no expected material impact on its business or financial results. MiniMed stated it is not aware of any compromises to its own IT systems as a result of this incident and does not anticipate a material impact on its business or financial results.

MiniMed Group, Inc.'s Chief Financial Officer, Chad Spooner, certified the company's Quarterly Report on Form 10-Q for the quarter ended January 23, 2026. The certification, made pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, confirms the report's compliance with the Securities Exchange Act of 1934. It also states that the financial information fairly presents the company's financial condition and results of operations in all material respects.